Sigil Biosciences | San Diego, CA

Building a new scaling engine
for biological intelligence

Not all ground truth is created equal. Frontier intelligence requires ground truth that expands
the space of observable, interconnected, and causally testable biology.
Sigil is building the engine to generate it.


Our Biological Intelligence Engine


01

New Biological Data

Physical AI expands observable biology
Physics-driven innovation opens inaccessible
biology to proven high-throughput methods.
New biology, same data formats

02

New Knowledge

New ground truth expands reasoning space
Broader biological coverage adds new context,
dimensionality and connections,
adding new and reinforced multimodal anchors.

03

Frontier Intelligence

Compounding knowledge expands learnable biology
Grounding strengthens the entire knowledge base.
Broader testable biology unlocks causal reasoning.
AI guides the next frontier-enabling experiments.

Today’s high-throughput tools produce vast biological data,
but only from a narrow slice of biology, which limits what AI can learn.

Sigil’s Biological Intelligence Engine combines proprietary physical and digital innovations to make previously inaccessible biology measurable with established methods, producing new ground truth in familiar, AI-ready formats.

2022


Initial IP filed;
first manual prototype developed

2023


Sigil PCT conversions backed
by externally manufactured prototype data

2026


First US patent granted;
clean prosecution history

100%


Founder developed
and funded to date


Physical AI expands observable biology. Digital AI compounds its value.
Powered by fully owned IP, the engine is designed to continuously expand and compound biological intelligence,
creating a foundation for future breakthroughs in drug discovery, precision medicine, and programmable biology.


Founding Team


Our Team

Our founding team has deep roots in life sciences, multiple ventures behind, and over ten years of innovating side by side.

Based in San Diego, CA

Founder & CEO

Raj Krishnan, PhD

Raj is scientist and engineer who creates the innovation that makes novel virtual biology possible.

Iryna Clark, MBA

Founder & COO

Iryna builds the conditions under which transformative technologies reach the world.

$102M


raised in prior ventures

53


issued patents in prior ventures

14


Peer reviewed publications

2


Sigil owned & developed patents


Advisory Team


Our multidisciplinary advisory board unites pioneering scientists from Stanford and UCSF, serial founders, and AI industry leaders, bringing deep expertise across biology, AI, and virtual biology with a proven track record of translating
breakthrough science into category-defining companies.

  • Michael Snyder, PhD

    Dr. Snyder is a pioneer in data-driven biology and precision medicine, Stanford professor and Director of the Center for Genomics and Personalized Medicine, with a track record of inventing foundational genomics technologies and generating large-scale multi-omic datasets. He has co-founded 17 companies (incl. 2 unicorns) with a combined enterprise value exceeding $6B.

  • Russ Altman, MD, PhD

    Dr. Altman is a leader in AI-driven biology and medicine, Stanford professor, National Academy of Medicine member, and Associate Director of Stanford HAI, with a track record of building foundational biological data platforms and advancing data-driven approaches to drug discovery.

  • Michelle Arkin, PhD

    Dr. Arkin is Vice Dean of Research Technology & Entrepreneurship at UCSF, Distinguished Professor of Pharmaceutical Chemistry, and Executive Director of the Small Molecule Discovery Center. A serial founder (Ambagon Therapeutics and Elgia Therapeutics) she has a track record of translating breakthrough science into therapeutic companies.

  • Trenton Norris

    Trent is a healthcare AI executive and serial builder with deep experience scaling emerging technologies, having led GTM and partnerships at NVIDIA and Microsoft.

  • Dave S. B. Hoon, PhD

    Dr. Hoon is a pioneer of circulating tumor DNA and liquid biopsy and a globally recognized leader in translational molecular oncology; Professor & Director of Translational Molecular Medicine, Saint John's Cancer Institute; 30+ patents, 475+ publications, 30+ NCI grants.